Vsevolozhsk

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

Researchers are evaluating the efficacy and safety of Dimephosphon4 in patients who have experienced an acute ischemic stroke. This multicenter, randomized, double-blind, placebo-controlled study focuses on adults aged 35 to 80 with verified hemispheric ischemic stroke confirmed by CT or MRI, and neurological scores between 5 and 15 on the NIH Stroke Scale. The trial aims to assess improvements in stroke outcomes using several clinical scales including the Modified Rankin Scale, NIH Stroke Scale, Mini-Mental State Examination, Montreal Cognitive Assessment, and EuroQol 5-Dimensions. Participants are randomly assigned to one of two groups one receiving Dimephosphon4 and the other a placebo. In both groups, from days 1 to 3, the assigned treatment is given as an intravenous infusion three times daily with at least 5 hours between doses. From days 4 to 14, the treatment is administered as an intravenous bolus, also three times daily. The dosing involves 2 grams of the study drug or placebo diluted appropriately for each administration. During the study, participants undergo a screening period lasting up to 48 hours, followed by treatment visits on days 1 through 14, with follow-up assessments up to day 90. Researchers will monitor clinical outcomes and neurological function using established scales at multiple time points, including days 8, 15, 30, and 90. Safety and mortality will also be tracked. The total duration of participation spans from initial screening through the last follow-up visit at day 90.